SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 2026

This week's digest spans three agencies and five enforcement and policy actions worth tracking: the SEC published a 2026–2030 strategic plan that elevates digital assets above all other rulemaking priorities; two civil cases dropped for real-estate fraud and insider trading; the FDA issued significant draft guidance for cell and gene therapy developers; and the FTC filed a clutch of consumer-protection actions while opening a window for X Corp. to unwind the 2022 Twitter privacy settlement.

The SEC released its draft strategic plan for fiscal years 2026–2030 on June 2, naming digital asset regulation as Objective 1.1 — the first item under its first goal. 1 That's a deliberate break from the Gensler era, when the agency relied on enforcement actions to set crypto policy rather than rulemaking. The plan calls for a "robust regulatory framework for digital assets and distributed ledger technology" applied with consistent, principles-based rules. It also names responsible AI adoption and EDGAR modernization as operational priorities.

The plan's second goal commits the agency to rolling back enforcement-by-litigation: the document explicitly says the SEC will "restore enforcement focused on fraud and manipulation" and will not use ad-hoc enforcement actions to expand its regulatory perimeter. Comments close July 2, 2026, under File No. DSP-3. 1

Phoenix American Hospitality / "Perch" Nelson — $86M real-estate fraud. The SEC filed a settled action on June 4 against Phoenix American Hospitality, LLC (PAH) and its president William Lee "Perch" Nelson, alleging they raised $86 million from more than 2,000 retail investors across two hotel investment funds from March 2022 through July 2024. 2 According to the complaint filed in the Northern District of Texas, PAH told investors one fund held equity in 11 hotels when it held a stake in just one, and paid investors with their own capital while describing those payments as operating returns. Nelson will pay roughly $118,000 and PAH will pay approximately $600,000; neither admitted to the allegations. 3

JianQing Li — insider trading in healthcare securities. On June 5, the SEC charged JianQing Li (S.D.N.Y., No. 1:26-cv-04778) with insider trading on material non-public information about at least 12 healthcare companies between February 2024 and October 2025. 4 Li worked as an investment analyst at an unidentified registered investment adviser focused on the healthcare sector. The SEC alleges he misappropriated confidential data about upcoming private placements and clinical trial results — information his employer had committed to keep confidential — and traded ahead of public announcements to pocket more than $320,000 in illegal profits. The agency is seeking a permanent injunction, disgorgement with pre-judgment interest, civil penalties, and a bar from associating with investment advisers. 4

Ross Gregory Erskine — final judgment entered. The SEC published a June 3 litigation release confirming a May 20 final judgment against Ross Gregory Erskine in a case first filed in 2021. 5 Erskine, acting as an unregistered broker-dealer for the LFS Funding Limited Partnership, raised more than $618,000 from investors using a private placement memorandum containing materially false statements. The judgment orders a permanent injunction against selling securities, $60,625 in disgorgement, $15,450 in pre-judgment interest, and a $100,000 civil penalty. Liability was established by summary judgment in August 2023; the final judgment closes out the monetary relief phase.

The FDA issued a draft guidance on June 2 titled "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing." 6 The document tells sponsors they can lean on existing CMC manufacturing data, nonclinical findings, and clinical information — including platform data that is publicly available — to avoid duplicating work already done for comparable products. The agency still expects a scientific rationale showing that the leveraged data is applicable to the specific product, but the upshot is a shorter development timeline for genome-editing therapies targeting rare and life-threatening diseases.

The Federal Register notice (Docket No. 2026-11054) sets a public comment deadline of September 1, 2026. 7 This guidance is separate from the animal-testing streamlining guidance issued the prior week (comment deadline July 30) — both are part of a visible 2026 acceleration push by CBER.

Ascension / AmSurg — 7 surgery center divestitures required. The FTC's most significant merger action this week cleared Ascension Health Alliance's $3.9 billion acquisition of AmSurg on June 2, but required Ascension to divest seven ambulatory surgery centers as a condition. 8 The centers earmarked for sale are located in Nashville (Tennessee), Panama City (Florida), Tulsa (Oklahoma), Waco (Texas), and Wichita (Kansas) — markets where the combined entity would otherwise have concentrated outpatient surgery capacity. Six centers will be divested to SCA Health's SC Affiliates subsidiary. Ascension closed the deal shortly after the consent order was announced. 9

Amare Global Holdings — MLM supplement fraud. On June 2, the FTC sued Amare Global Holdings Inc. and three principals in California federal court for allegedly misrepresenting the health benefits of dietary supplements sold through a multi-level marketing network. 10 The complaint names CEO David Chung, founding brand partner Patrick Hintze, and former chief science officer Shawn Talbott. Products including Kids Happy Juice, Kids Mood+, and the Happy Juice Product Pack were promoted on Instagram, TikTok, YouTube, and Facebook with claims that they could "cure, treat, or mitigate depression, anxiety, and ADHD" in children. The FTC also alleged that Hintze and Talbott are already subject to prior FTC orders barring false health claims — making this a repeat-offender case. The agency also challenges deceptive earnings claims to MLM recruits. 11

Illuminate Education — final consent order for student data breach. The FTC finalized a modified consent order against Wisconsin-based Illuminate Education on June 5, following a public comment period. 12 The underlying breach, which occurred between December 2021 and January 2022, exposed personal data on roughly 10.1 million students — including health-related information, email addresses, dates of birth, and school records — after a hacker accessed cloud databases using the credentials of a former employee who had left the company three and a half years earlier. 13 The order carries no monetary penalty; instead it mandates deletion of data no longer needed for services, a formal data retention plan, a comprehensive information security program, and a prohibition on misrepresenting the company's data protection capabilities. The 2-0 vote to finalize reflects a stricter-on-process, lighter-on-fines approach the current commission has signaled in data security cases.

X Corp. / Twitter — FTC opens comment period on consent order petition. On June 3, the FTC announced it is seeking public comment on a petition from X Corp. asking the agency to set aside or significantly modify the 2022 consent order that imposed a $150 million fine and 20 years of privacy oversight on Twitter. 14 X Corp. argues the order was imposed on a legal entity — the pre-acquisition Twitter, Inc. — that "no longer exists," and that the current X Corp. has built a "world-class" privacy and data protection program. The company also contends that maintaining the settlement constrains its ability to use training data for AI development — arguing that "setting aside or modifying the order is critical to advancing American leadership in artificial intelligence." The comment period closes July 2, 2026. Privacy advocates are expected to push back, given that the original violation involved using two-factor authentication phone numbers for targeted advertising. 15

Diversity Lab — DEI consultancy dissolves after FTC probe. The FTC announced June 5 that Diversity Lab LLC, a California-based DEI consultancy best known for its law firm diversity programs, has permanently ceased operations and filed dissolution paperwork. 16 The FTC had been investigating whether the organization's programs — including the "Mansfield Rule" certification used by more than 300 law firms — constituted anticompetitive coordination. According to Diversity Lab's leadership, the agency sought to impose a broad settlement barring it from collecting or sharing firm demographic data. Facing four months of FTC engagement, "pushed to the brink of bankruptcy" with no viable path forward, the group shut down rather than continue contesting the probe. All client data is being eliminated or destroyed as part of the dissolution. 17